Navco Pharmaceuticals Inc.
NAV.V
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -280.45% | 60.12% | 37.75% | 20.63% | 113.84% |
| Total Depreciation and Amortization | -97.57% | -39.33% | 42.64% | 65.95% | 95.57% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 142.50% | -70.39% | -10.34% | -10.50% | -161.66% |
| Change in Net Operating Assets | -72.84% | 172.69% | 167.42% | 185.90% | 187.72% |
| Cash from Operations | 93.73% | 97.25% | 94.70% | 85.91% | 47.68% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 162.03% | -- | -- | -- | 648.00% |
| Total Debt Repaid | 53.92% | 72.71% | 60.76% | 72.80% | 76.02% |
| Issuance of Common Stock | -- | -- | -- | -- | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -1,176.19% |
| Cash from Financing | 224.66% | -89.18% | -98.68% | -98.72% | -101.49% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 99.28% | 99.81% | -246.82% | -201.39% | -199.66% |